NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 01/06/21

NeuroBo Pharmaceuticals (NRBO) has acquired ANA Therapeutics, a biotechnology company developing ANA-001, currently in Phase 2/3 clinical trials as a treatment for COVID-19."This is an exciting and transformative acquisition for NeuroBo that expands our pipeline with a late-stage cl...

NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program Transformative Acquisition Deepens Pipeline with In-Process Phase 2/3 Clinical Study of Proprietary Oral Formulation of Niclosamide for the Treatment of COVID-19 Development T...

NeuroBo Pharmaceuticals (NRBO): Q3 GAAP EPS of -$0.19 misses by $0.02.Cash and equivalents were $12.4M as of Sep. 30, 2020, compared with $13.9M at Dec. 31, 2019; expects that its cash position will be adequate to fund operations into 3Q21."Given the global resurgence of COVID-19, we hav...

NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire BOSTON, Nov. 13, 2020 BOSTON , Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and co...

BOSTON , Sept. 2, 2020 /PRNewswire/ --  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that Do...

NeuroBo Pharmaceuticals (NASDAQ: NRBO ) : Q2 GAAP EPS of -$0.15 beats by $0.12 . More news on: NeuroBo Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BOSTON , Aug. 11, 2020 /PRNewswire/ --  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financia...

BOSTON , June 16, 2020 /PRNewswire/ --  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today reported that the ...

BOSTON , May 26, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it receiv...

NeuroBo Pharmaceuticals (NASDAQ: NRBO ): Q1 GAAP EPS of -$0.30 misses by $0.20 . More news on: NeuroBo Pharmaceuticals, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...